Trial Profile
Bioavailability and Pharmacokinetics of 50 mg BI 135585 XX Administered as Tablet With and Without Food in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 135585 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Apr 2011 Status changed from recruiting to completed, according to ClinicalTrials.gov.
- 10 Feb 2011 New trial record